Aberdeen Wealth Management’s Teva Pharmaceuticals TEVA Stock Holding History

Aberdeen Wealth Management’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.39K	Buy	+100	New	+$3.33K	﹤0.01%	383

Other funds holding TEVA

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HIIFS

Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return

Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return

WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return

Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return

MIFH

Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

LIM

Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

Aberdeen Wealth Management's TEVA Position: Q2 2026 in Review

Aberdeen Wealth Management opened a new position in Teva Pharmaceuticals (TEVA) in Q2 2026: 100 shares worth $3.39K. The stake represents ﹤0.01% of the portfolio and ranks #383 among its holdings.

672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

Aberdeen Wealth Management held 100 shares of Teva Pharmaceuticals worth $3.39K as of Q2 2026.
Teva Pharmaceuticals was a new Aberdeen Wealth Management position in Q2 2026.
Teva Pharmaceuticals made up ﹤0.01% of Aberdeen Wealth Management's portfolio in Q2 2026, its #383 holding.
672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on Aberdeen Wealth Management's 13F filing for Q2 2026, filed 13 Aug 2026.